Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.
A. D. Pardanani
Research Funding - Cytopia
D. Caramazza
No relevant relationships to disclose
G. George
No relevant relationships to disclose
T. L. Lasho
No relevant relationships to disclose
W. J. Hogan
No relevant relationships to disclose
M. R. Litzow
No relevant relationships to disclose
K. Begna
No relevant relationships to disclose
C. A. Hanson
No relevant relationships to disclose
R. F. McClure
No relevant relationships to disclose
L. M. Bavisotto
No relevant relationships to disclose
G. Smith
Employment or Leadership Position - YM BioSciences
Stock Ownership - YM BioSciences
M. Kowalski
Employment or Leadership Position - YM BioSciences
Stock Ownership - YM BioSciences
S. Sirhan
No relevant relationships to disclose
A. W. Roberts
No relevant relationships to disclose
V. Gupta
No relevant relationships to disclose
J. Gotlib
No relevant relationships to disclose
A. Tefferi
No relevant relationships to disclose